Samantha Hocking

Associate Professor Samantha Hocking is an academic affiliated with the University of Sydney's Faculty of Medicine and Health and the Charles Perkins Centre. She serves as Co-Director of the Royal Prince Alfred Hospital Clinic and has held leadership roles in obesity and diabetes research since at least 2017. Her research focuses on translational medicine, particularly obesity treatment strategies, diabetes management innovations, and metabolic disorder interventions.

Education details are not explicitly provided in the text, but her professional trajectory suggests advanced training in medicine and endocrinology. Key research areas include pharmacotherapy for obesity, mechanisms of insulin resistance, and lifestyle interventions for metabolic diseases. She has contributed to developing clinical tools like the EOSS-2 Risk Tool and led multi-institutional studies involving mouse models and human clinical trials.

Her work spans international collaborations with institutions in China and Southeast Asia, emphasizing culturally tailored healthcare solutions. Notable grants include the Charles Perkins Centre Research Award (Leadership) and NHMRC Ideas Grant. Research interests also include gestational diabetes management, fatty liver disease, and the interplay between adipose tissue distribution and metabolic health.

She has been involved in 7 funded grants since 2015, including studies on bariatric surgery outcomes, stroke treatment with GLP-1 agonists, and diabetes risk prediction tools. No formal advisees are listed, though her roles suggest involvement in training programs.

Her research group explores adipose tissue transplantation effects in murine models, linking basic science discoveries to clinical applications. Current projects include the RESET1 trial (2024) and DiRECT-Aus initiative, focusing on semaglutide and lifestyle interventions respectively.